A first-in-human study of [⁶⁸Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death.

ABSTRACT:

Purpose

This study assesses human biodistribution, radiation dosimetry, safety and tumour uptake of cell death indicator labelled with ⁶⁸Ga ([⁶⁸Ga]Ga-CDI), a novel radiopharmaceutical that can image multiple forms of cell death.

Methods

Five participants with at least one extracranial site of solid malignancy > 2 cm and no active cancer treatment in the 8 weeks prior to the study were enrolled. Participants were administered 205 ± 4.1 MBq (range, 200-211 MBq) of [⁶⁸Ga]Ga-CDI and 8 serial PET scans acquired: the first commencing immediately and the last 3 h later. Participants were monitored for clinical, laboratory and electrocardiographic side effects and adverse events. Urine and blood radioactivity was measured. Spherical volumes of intere

SUBMITTER: Ho Shon I 

PROVIDER: S-EPMC9525422 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature